No Data
Zhejiang Huahai Pharmaceutical (600521.SH): The subsidiary's drug clinical trials have achieved the primary efficacy endpoint and all key secondary efficacy endpoints.
On March 4, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that its subsidiary Shanghai Huotai Biomedical Co., Ltd. (referred to as "Huotai"), along with Huabo Biomedical Technology (Shanghai) Co., Ltd. (referred to as "Huabo Biomedical," a wholly-owned subsidiary of Huotai), has independently developed the HB0034 injection for the treatment of acute outbreaks of generalized pustular psoriasis. The multicenter, double-blind, randomized, placebo-controlled pivotal clinical trial has met the primary efficacy endpoint and all key secondary efficacy endpoints.
Zhejiang Huahai Pharmaceutical Gets Drug Registration for Seizure Treatment
Zhejiang Huahai Pharmaceutical's Public Transfer of Antidepressant Patent Ends Without Deal
Zhejiang Huahai Pharmaceutical (600521.SH): The company has applied AI technology in the early stages of Innovative Drugs research and development.
Gelonghui reported on February 25 that Zhejiang Huahai Pharmaceutical (600521.SH) stated on the investor interaction platform that the company attaches great importance to the role of AI technology in drug development. Currently, the company has applied AI technology in the early stages of Innovative Drugs research and development, including target discovery and validation, as well as compound screening and design. In addition, the company is actively promoting the localized deployment of DeepSeek to further improve research and development efficiency, while continuing to explore the application of AI technology in various scenarios such as research and development, clinical trials, and production.
Huahai Pharmaceutical Units Get Approval for Asthma Drug Clinical Trials
Zhejiang Huahai Pharmaceutical (600521.SH): HB0056 injection has obtained approval for clinical drug trials.
On February 21, Gelonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced that its subsidiary Shanghai Huatai Biological Pharmaceutical Co., Ltd. and Huabo Biomedical Technology (Shanghai) Co., Ltd. (a wholly-owned subsidiary of Huatai) received the 'Approval Notice for Drug Clinical Trials' issued by the National Medical Products Administration for the HB0056 injection. HB0056 is a bispecific antibody that uses anti-TSLP (thymic stromal lymphopoietin) humanized monoclonal antibody as the parent antibody, with an anti-IL-11 (interleukin-11) single-chain nanoantibody linked at the N-terminus.
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
